Shardul Amarchand Mangaldas advised Novo Holdings A/S in connection with its investment in Medgenome Inc., as a part of the company’s USD 47.5 million Series E funding round, co-led by Novo Holdings A/S and Maj Invest.
This investment will enable the company in expanding its genomics and integrated diagnostics solutions across India and other emerging markets with a focus on early detection and targeted disease management through affordable genetic and integrated diagnostics tools.
SAM team provided end-to-end support on the transaction.
The SAM & Co. transaction team was led by Nishant Singh, Partner and included Saksham Madan, Principal Associate and Charith Reddy, Senior Associate.
Other parties to the transaction included Sofina Ventures S.A., Maj Invest Minorities II K/S, and MedGenome Inc., with Argus Partners advising MedGenome Inc.
